Regulated information - Inside
information Breda, the
Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq:
ARGX) a clinical-stage biotechnology company developing a deep
pipeline of differentiated antibody-based therapies for the
treatment of severe autoimmune diseases and cancer, announced today
the pricing of its public offering in the United States (the
Offering) with anticipated gross proceeds totalling approximately
$231 million from the sale of 4,440,000 American Depository Shares
(ADSs), at a price to the public of $52.00 per ADS. argenx
increased the Offering from the initially filed offering size of
$150 million.
All of the ADSs are being offered by argenx, and
each of the ADSs offered represents the right to receive one
ordinary share, nominal value of €0.10 per share. argenx has
granted the underwriters an option to purchase up to an additional
666,000 ADSs, representing 15% of the ADSs sold in the Offering.
This option can be exercised during the 30-day period commencing
December 13, 2017. The Offering is expected to close on December
18, 2017, subject to customary closing conditions. argenx's ADSs
are currently listed on the Nasdaq Global Select Market under the
symbol "ARGX," and argenx's ordinary shares are currently listed on
Euronext Brussels.
Cowen and Piper Jaffray & Co. are acting as
joint bookrunning managers for the Offering, and JMP Securities and
Wedbush PacGrow are acting as co-managers. Kempen & Co is
argenx's advisor in connection with the Offering.
A registration statement relating to and
describing the terms of the Offering has been filed with, and was
declared effective by, the U.S. Securities and Exchange Commission
(SEC) on December 13, 2017. This registration statement can be
accessed through the SEC's website at.
The Offering is being made only by means of a
prospectus forming part of the effective registration statement.
When available, copies of the final prospectus can be obtained for
free from Cowen and Company, LLC, c/o Broadridge Financial
Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attn:
Prospectus Department, by telephone at (631) 274-2806 or by fax at
(631) 254-7140 or from Piper Jaffray & Co., Attn: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55403, or by
telephone at (800)747-3924, or by email at prospectus@pjc.com.
This press release is for information purposes
only and does not constitute, and should not be construed as, an
offer to sell or the solicitation of an offer to buy or subscribe
to any securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale is not
permitted or to any person or entity to whom it is unlawful to make
such offer, solicitation or sale. Reference is also made to the
restrictions set out in "Important information" below. This press
release is not for publication or distribution, directly or
indirectly, in or into any state or jurisdiction into which doing
so would be unlawful or where a prior registration or approval is
required for such purpose.
About argenxargenx is a clinical-stage
biotechnology company developing a deep pipeline of differentiated
antibody-based therapies for the treatment of severe autoimmune
diseases and cancer. We are focused on developing product
candidates with the potential to be either first-in-class against
novel targets or best-in-class against known, but complex, targets
in order to treat diseases with a significant unmet medical need.
Our ability to execute on this focus is enabled by our suite of
differentiated technologies. Our SIMPLE Antibody(TM) Platform,
based on the powerful llama immune system, allows us to exploit
novel and complex targets, and our three antibody engineering
technologies are designed to enable us to expand the therapeutic
index of our product candidates.
www.argenx.com
For further information, please
contact:
Joke Comijn, Corporate Communications Manager
+32 (0)477 77 29 44+32 (0)9 310 34 19info@arGEN-X.com
Beth DelGiacco (US IR)Stern Investor Relations+1
212 362 1200beth@sternir.com
Forward-looking StatementsThe contents of
this announcement include statements that are, or may be deemed to
be, "forward-looking statements." These forward-looking statements
can be identified by the use of forward-looking terminology,
including the terms "believes," "estimates," "anticipates,"
"expects," "intends," "may," "will," or "should," and include
statements argenx makes concerning the anticipated closing of the
public offering. By their nature, forward-looking statements
involve risks and uncertainties related to the completion of the
Offering on the anticipated terms, or at all, and readers are
cautioned that any such forward-looking statements are not
guarantees of future performance. These risks and uncertainties
include, but are not limited to, market conditions and the
satisfaction of customary closing conditions related to the
Offering. argenx's actual results may differ materially from those
predicted by the forward-looking statements as a result of various
important factors, including argenx's expectations regarding its
the inherent uncertainties associated with competitive
developments, preclinical and clinical trial and product
development activities and regulatory approval requirements;
argenx's reliance on collaborations with third parties; estimating
the commercial potential of argenx's product candidates; argenx's
ability to obtain and maintain protection of intellectual property
for its technologies and drugs; argenx's limited operating history;
and argenx's ability to obtain additional funding for operations
and to complete the development and commercialization of its
product candidates. A further list and description of these risks,
uncertainties and other risks can be found in argenx's SEC filings
and reports, including in the prospectus related to argenx's U.S.
public offering filed with the SEC pursuant to Rule 424(b) of the
Securities Act of 1933, as amended, as well as subsequent filings
and reports filed by argenx with the SEC. Given these
uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this
document. argenx undertakes no obligation to publicly update or
revise the information in this press release, including any
forward-looking statements, except as may be required by law.
Important informationNo public offering
will be made and no one has taken any action that would, or is
intended to, permit a public offering in any country or
jurisdiction, other than the United States, where any such action
is required, including in the European Economic Area. In the
European Economic Area, the transaction to which this press release
relates will only be available to, and will be engaged in only
with, qualified investors within the meaning of Directive
2003/71/EC (together with any applicable implementing measures in
the relevant member state of the European Economic Area and as
amended, including by Directive 2010/73/EU, to the extent
implemented in the relevant member state).
In addition, in the United Kingdom, the
transaction to which this press release relates will only be
available to, and will be engaged in only with, investment
professionals falling within Article 19(5) of the Financial
Services and Markets Act (Financial Promotion) Order 2005, as
amended (the Order), persons falling within Article 49(2)(a) to (d)
of the Order, and other persons to whom this announcement may
lawfully be communicated (all such persons together being referred
to as "relevant persons"). The securities referred to herein are
only available to, and any invitation, offer or agreement to
subscribe, purchase or otherwise acquire such securities will be
engaged in only with relevant persons. Any person who is not a
relevant person should not act or rely on this communication or any
of its contents.
Argen X (EU:ARGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Argen X (EU:ARGX)
Historical Stock Chart
From Apr 2023 to Apr 2024